The Wnt ligand secretion mediator wntless (WLS) has also been shown to confer enzalutamide resistance in prostate cancer cells [57], and Wnt target genes LEF1 and WNT5a are elevated in LNCaP-AI cells (cultured in androgen-depleted media) [47]. Here, WNT5A is linked to prostate cancer.